CS-121
Phase 1Biologic
CS-121 is one of 29 biologic programs targeting Familial Chylomicronemia Syndrome. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
32 competitors in Adolescent
#DrugCompanyPhaseTrials
1Zoloft
VViatris Specialty LLC
Approved
Fanapt
VVanda Pharmaceuticals
Approved
Abilify
OtsukaApproved
Sunlenca
GileadPhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Brintellix
TakedaPhase 2
Cymbalta
Jazz PharmaceuticalsPhase 2
Camptosar
PfizerPhase 2
Valdoxan
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS-121. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details